Evolution of Vaginal Candida Species Recovered from Human Immunodeficiency Virus‐Infected Women Receiving Fluconazole Prophylaxis: The Emergence of Candida glabrata?
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The effect of fluconazole prophylaxis on the vaginal flora of 323 human immunodeficiency virus-infected women was evaluated in a multicenter, randomized, double-blind, placebo-controlled trial. Women with CD4 cell counts of < or = 300/mm3 received either 200 mg of fluconazole per week or placebo. Vaginal surveillance cultures were performed every 3 months. After a follow-up of 29 months, Candida albicans was recovered from 53% of patients receiving fluconazole and 68% of patients assigned placebo. Fluconazole was associated with a 50% reduction in the odds of being colonized with C. albicans but with higher rates for non-albicans Candida species. Candida glabrata was recovered from 40 women assigned fluconazole and 29 assigned placebo (relative odds, 1.96; 95% confidence interval, 0.98-3.94). Fluconazole had an early and persistent effect on the vaginal mycoflora, with the emergence of C. glabrata vaginal colonization within the first 6 months. The effect of fluconazole prophylaxis can be attributed to the reduction in vaginal C. albicans colonization; however, C. glabrata colonization rapidly supervened.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there was a statistically significant increase in the rate of infections due to Candida glabrata, which is now the second most common cause of bloodstream and mucosal infections in the United States (6, 48, 65, 69).”
From Functional Genomic Analysis of Fluconazole Susceptibility in the Pathogenic Yeast Candida glabrata : Roles of Calcium Signaling and Mitochondria (2004) · cites this paper as [69]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Plackett, R. L., & Cox, D. R. (1971) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344247 · Cited by 2,264 · cited 1×
“multivariate logistic regression analysis [17].”
Generalized linear mixed models a pseudo-likelihood approach
Wolfinger, R., & O'connell, M. (1993) · Journal of Statistical Computation and Simulation · doi:10.1080/00949659308811554 · Cited by 1,271
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Klein, R. S., Harris, C. A., Small, C. B., Moll, B., Lesser, M., & Friedland, G. H. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408093110602 · Cited by 863 · cited 1×
“perficial (mucosal) infections, produced by opportunistic fungal pathogens belonging to the Candida species [1-4].”
BackgroundEdwards, Jr., Bodey, G. P., Bowden, R. A., Buchner, T., de Pauw, B. E., Filler, S. G., Ghannoum, M. A., Glauser, M., Herbrecht, R., Kauffman, C. A., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/514504 · Cited by 418 · cited 1×
“[24].”
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1847 · Cited by 340
Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N., & Kauffman, C. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90300-x · Cited by 322 · cited 1×
“Both the increased incidence in fungal infections and the consequent increased use of antifungals are thought to select for fungal populations that are more resistant to antifungals [19-22].”
BackgroundPowderly, W. G., Finkelstein, D. M., Feinberg, J., Frame, P., He, W., van der Horst, C., Koletar, S. L., Eyster, M. E., Carey, J., Waskin, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503163321102 · Cited by 318 · cited 4×
“recently performed a prospective, randomized trial comparing fluconazole (200 mg/d) with clotrimazole troches [13].”
BackgroundInfluentialOpportunistic diseases reported in AIDS patients: frequencies, associations, and trends.
Selik, R. M., Starcher, E. T., & Curran, J. W. (1987) · PubMed · Cited by 270
Cited by
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“Chronic use of fluconazole in HIV-infected women has been associated with increased vaginal carriage of non-albicans species of Candida [320], but the significance of this observation is uncertain.”
BackgroundSelf-citationEpidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900
A yeast by any other name: Candida glabrata and its interaction with the host
Kaur, R., Domergue, R., Zupancic, M. L., & Cormack, B. P. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.06.012 · Cited by 271
De Las Peñas, A., Pan, S.-J., Castaño, I., Alder, J., Cregg, R., & Cormack, B. P. (2003) · Genes & Development · doi:10.1101/gad.1121003 · Cited by 268
“C. glabrata, a haploid yeast, accounts for upwards of 15% of isolates from the bloodstream as well as from mucosal sites (Schuman et al. 1998; Pfaller et al. 1999, 2001; Vazquez et al. 1999).”
BackgroundNicotinic Acid Limitation Regulates Silencing of Candida Adhesins During UTI
Domergue, R., Castaño, I., De Las Peñas, A., Zupancic, M., Lockatell, V., Hebel, J. R., Johnson, D., & Cormack, B. P. (2005) · Science · doi:10.1126/science.1108640 · Cited by 249
Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216
Telomere length control and transcriptional regulation of subtelomeric adhesins in Candida glabrata
Castaño, I., Pan, S., Zupancic, M., Hennequin, C., Dujon, B., & Cormack, B. P. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04465.x · Cited by 188
An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis
Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018) · Journal of Fungi · doi:10.3390/jof4040121 · Cited by 182
“This finding is thought to be due to long term administration of fluconazole for prophylaxis against other fungal opportunistic infections in HIV positive individuals [89,90].”
BackgroundKaur, R., Castaño, I., & Cormack, B. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1600-1613.2004 · Cited by 167
“Perhaps related to its increasing prevalence, C. glabrata is innately resistant to fluconazole (49) and indeed is often isolated as a replacement species in patients receiving fluconazole treatment (47, 48, 69 ).”
BackgroundGeddes‐McAlister, J., & Shapiro, R. S. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 159
Frieman, M. B., McCaffery, J. M., & Cormack, B. P. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03166.x · Cited by 149
Iraqui, I., Garcia‐Sanchez, S., Aubert, S., Dromer, F., Ghigo, J., D’Enfert, C., & Janbon, G. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04475.x · Cited by 126
The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0016-6 · Cited by 127
Self-citationChen, K.-H., Miyazaki, T., Tsai, H., & Bennett, J. E. (2006) · Gene · doi:10.1016/j.gene.2006.08.010 · Cited by 106
Tn 7-Based Genome-Wide Random Insertional Mutagenesis of Candida glabrata
Castaño, I., Kaur, R., Pan, S., Cregg, R., Peñas, A. D. L., Guo, N., Biery, M. C., Craig, N. L., & Cormack, B. P. (2003) · Genome Research · doi:10.1101/gr.848203 · Cited by 77
“In frequency of isolation, C. glabrata is second only to C. albicans and is responsible for 15%–20% of both mucosal (Schuman et al. 1998; Vazquez et al. 1999) and systemic (Pfaller et al. 1999, 2001) candidiasis; in spite of this epidemiological similarity, C. glabrata is phylogenetically distant…”
BackgroundMathema, B., Cross, E., Dun, E., Park, S., Bedell, J., Slade, B., Williams, M., Riley, L., Chaturvedi, V., & Perlin, D. S. (2001) · Clinical Infectious Diseases · doi:10.1086/322600 · Cited by 65
Vazquez, J. A., Peng, G., Sobel, J. D., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. O. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322641 · Cited by 57
“1070 • CID 2001:33 (1 October) • HIV/AIDS randomized, placebo-controlled trial of fluconazole (200 mg per week) for the prevention of mucosal candidiasis in HIVinfected women with CD4 cell counts of 300 cells/mm(3) [13, 20].”
BackgroundSelf-citationCross, E. W., Park, S., & Perlin, D. S. (2000) · Microbial Drug Resistance · doi:10.1089/107662900419474 · Cited by 56
“7,41,44 In the past decade, there has been a significant increase in the prevalence of drug-resistant fungal infections in hospitalized patients due to Candida spp. for both mucosal and systemic diseases.”
UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata
Whaley, S. G., Caudle, K. E., Vermitsky, J.-P., Chadwick, S. G., Toner, G., Barker, K. S., Gygax, S. E., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02217-13 · Cited by 52
Invasive Oesophageal Candidiasis: Current and Developing Treatment Options
Vázquez, J. A. (2003) · Drugs · doi:10.2165/00003495-200363100-00004 · Cited by 53
Niimi, M., Nagai, Y., Niimi, K., Wada, S.-I., Cannon, R. D., Uehara, Y., & Monk, B. C. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00668-2 · Cited by 40
White, D., & Vanthuyne, A. (2006) · Sexually Transmitted Infections · doi:10.1136/sti.2006.023168 · Cited by 37
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection
Ray, A., Ray, S., George, A. T., & Swaminathan, N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008739.pub2 · Cited by 38
Gallo-Ebert, C., Donigan, M., Stroke, I. L., Swanson, R. N., Manners, M. T., Francisco, J., Toner, G., Gallagher, D., Huang, C.-Y., Gygax, S. E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01677-13 · Cited by 32
“Candida species cause systemic infections in the immunocom-promised, such as HIV patients, those receiving cancer chemotherapy, and organ transplant patients (1–5).”
BackgroundWestwater, C., Schofield, D. A., Nicholas, P. J., Paulling, E. E., & Balish, E. (2007) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2007.00287.x · Cited by 27
“To date, very little is known about the specific virulence mechanism(s) employed by NACS and the specific defense components needed to protect the host from C. glabrata-associated infections.”
BackgroundThe emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia
Sobel, J. D. (2007) · Current Fungal Infection Reports · doi:10.1007/s12281-007-0007-6 · Cited by 26
Self-citationLimitations of antifungal agents in the treatment of Candida vaginitis: future challenges
Sobel, J. D. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0088 · Cited by 22
Self-citationRibeiro, M. A., Miranda, A. E., Gambale, W., & Paula, C. R. (2004) · Mycopathologia · doi:10.1023/b:myco.0000024173.02010.a5 · Cited by 22
Vahedpoor, Z., Abastabar, M., Sehat, M., Talebian, P., fini, T. F., Dastanpour, Z., Haghani, I., Chelongarian, R., & Nazeri, M. (2021) · Current Medical Mycology · doi:10.18502/cmm.7.3.7803 · Cited by 21
“Vaginal discharge and burning were the most common symptoms in both groups, which is similar to the results of other studies [13, 40].”
ResultPrimary antifungal prophylaxis for cryptococcal disease in HIV-positive people
Awotiwon, A., Johnson, S., Rutherford, G. W., Meintjes, G., & Eshun‐Wilson, I. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004773.pub3 · Cited by 19
Arv1 lipid transporter function is conserved between pathogenic and nonpathogenic fungi
Ebert, C., McCourt, P. C., Donigan, M., Villasmil, M. L., Chen, W., Pandya, D., Franco, J., Romano, D. R., Chadwick, S. G., Gygax, S. E., et al. (2011) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2011.11.006 · Cited by 14
Antifungal resistance in yeast vaginitis.
Dun, E. (1999) · PubMed Central · Cited by 19
Makarova, N. U., Pokrowsky, V. V., Kravchenko, A. V., Serebrovskaya, L. V., James, M. J., McNeil, M. M., Lasker, B. A., Warnock, D. W., & Reiss, E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.1833-1837.2003 · Cited by 20
“Fluconazole has been successful in treating OPC and esophageal candidiasis in HIV-infected patients (14, 20, 23), but its long-term use raises the possibility of the acquisition of resistance by the yeast Candida albicans (7, 12, 17, 25) and the emergence of other Candida species, such as C. krusei and C. glabrata, wi…”
BackgroundGynecologic Care of Women Infected With HIV
Korn, A. P. (2001) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200106000-00011 · Cited by 11
Dalisay, D. S., Rogers, E. W., & Molinski, T. F. (2021) · Marine Drugs · doi:10.3390/md19030126 · Cited by 11
Antimicrobial resistance in vulvovaginitis
Sobel, J. D. (2001) · Current Infectious Disease Reports · doi:10.1007/s11908-001-0093-5 · Cited by 12
“These patients presented with azole refractory disease in which high-level fluconazole resistance was present, but in addition, cross-resistance to all other available systemic azoles was evident [8, 9 ].”
BackgroundSelf-citationClinical Syndromes: Candida and Candidosis
Ruhnke, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-92300-0_4 · Cited by 8
Kre29p is a novel nuclear protein involved in DNA repair and mitotic fidelity in Candida glabrata
Miyazaki, T., Tsai, H., & Bennett, J. E. (2006) · Current Genetics · doi:10.1007/s00294-006-0072-3 · Cited by 7
“The incidence of systemic infection is dramatically increasing perhaps due to the extensive use of azole antifungals, to which C. glabrata is relatively resistant (Fidel et al. 1999; Vazquez et al. 1999; Pfaller et al. 2002).”
BackgroundThe Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_18 · Cited by 7
Self-citationHuman Immunodeficiency Virus Infection in Women
Cohn, S. E., & Clark, R. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00128-4 · Cited by 9
Ayadpoor, A., & Hall, S. (2011) · Osteopathic Family Physician · doi:10.1016/j.osfp.2011.06.003 · Cited by 4
Infectious Vulvovaginitis: Current Trends and Management
Ponte, C. D. (2000) · Journal of Pharmacy Technology · doi:10.1177/875512250001600305 · Cited by 3
Powderly, W. G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0695-2.00028-6 · Cited by 3
The Role of Resistance in Candida Infections: Epidemiology and Treatment
Sobel, J. D., & Akins, R. A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-595-8_18 · Cited by 4
Self-citationDevitt, E. J., & Powderly, W. G. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-2882-6.50037-x · Cited by 2
Selected Issues in the Treatment of Women Infected With HIV
Young, M., & Clark, R. A. (2001) · Clinical Obstetrics & Gynecology · doi:10.1097/00003081-200106000-00007 · Cited by 1
Non- albicans Candida Infections
Sobel, J. D., & Revankar, S. G. (2014) · ASM Press eBooks · doi:10.1128/9781555815592.ch19
Self-citationEmerging Candida spp. Infections
Georgiev, V. S. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-296-8_21
Pomeroy, C., & Goodman, N. L. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-036-0_6
Thornton, A., Adkins, D. A., & Arno, J. N. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-036-0_11
Human Immunodeficiency Virus Infection in Women
Cohn, S. E., & Clark, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00126-0
Metadata
- Authors
- Vazquez, J. A., Sobel, J. D., Peng, G., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. I. A.
- Affiliations
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-05
- Volume
- 28
- Issue
- 5
- Pages
- 1025-1031
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2131249166
- Cited by
- 51
- References
- 28
- Citations by year
- 2021: 2 · 2018: 4 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Keywords
- fluconazole prophylaxis, Candida glabrata, Candida albicans, vaginal candidiasis, HIV infection, non-albicans Candida, antifungal prophylaxis, candidal colonization, CD4 count
- MeSH terms
- Antifungal Agents, Candida, Candida albicans, Candidiasis, Vulvovaginal, Double-Blind Method, Female, Humans, Risk Factors, Fluconazole, AIDS-Related Opportunistic Infections, CD4 Lymphocyte Count, Antibiotic Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.